BioAge Labs (NASDAQ:BIOA) Stock Rating Upgraded by UBS Group

BioAge Labs (NASDAQ:BIOA) was upgraded by equities researchers at UBS Group to a “hold” rating in a report released on Sunday, Zacks reports.

BIOA has been the topic of several other reports. Jefferies Financial Group set a $21.00 price objective on shares of BioAge Labs in a research report on Friday, July 31st. BTIG Research reiterated a “buy” rating and set a $40.00 target price on shares of BioAge Labs in a research report on Tuesday, September 8th. Needham & Company LLC cut their price target on shares of BioAge Labs from $50.00 to $35.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Wall Street Zen lowered shares of BioAge Labs from a “sell” rating to a “strong sell” rating in a report on Saturday. Finally, Weiss Ratings lowered shares of BioAge Labs from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, October 8th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

BioAge Labs Stock Performance

BioAge Labs stock opened at $5.57 on Friday. BioAge Labs has a fifty-two week low of $5.04 and a fifty-two week high of $25.95. The stock has a market cap of $255.66 million, a P/E ratio of -2.34 and a beta of 1.08. The firm’s fifty day moving average price is $8.75 and its 200-day moving average price is $15.39.

BioAge Labs (NASDAQ:BIOA) last posted its earnings results on Wednesday, August 5th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.07. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%. The business had revenue of $2.45 million during the quarter. Sell-side analysts predict that BioAge Labs will post -2.45 earnings per share for the current year.

Institutional Trading of BioAge Labs

Several hedge funds and other institutional investors have recently bought and sold shares of BIOA. BlackRock Inc. bought a new stake in shares of BioAge Labs in the 2nd quarter valued at about $69,831,000. Jupiter Topco LLC bought a new position in BioAge Labs during the 2nd quarter worth approximately $52,597,000. Janus Henderson Group PLC grew its position in BioAge Labs by 411.8% during the 1st quarter. Janus Henderson Group PLC now owns 2,094,270 shares of the company’s stock worth $36,597,000 after acquiring an additional 1,685,063 shares during the last quarter. Octagon Capital Advisors LP increased its stake in BioAge Labs by 9.4% in the 1st quarter. Octagon Capital Advisors LP now owns 1,748,000 shares of the company’s stock worth $30,573,000 after purchasing an additional 150,000 shares during the period. Finally, Walleye Capital LLC purchased a new position in BioAge Labs in the 2nd quarter worth approximately $8,686,000.

About BioAge Labs

BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines for diseases associated with aging. The company uses human longevity data, machine learning and biology research to identify therapeutic targets and develop treatments intended to address the biological drivers of aging and age-related decline.

BioAge’s pipeline has included azelaprag, formerly known as BGE-105, an investigational small-molecule agonist of the apelin receptor. The company has evaluated azelaprag in clinical studies involving muscle function and has also investigated its potential use in combination with incretin-based medicines for obesity.